Brazine

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Brazine

What is Brazine? Identity and Composition

Property Description
Active Ingredient Cinnarizine
Form Tablet (Oral)
Pharmacological Class H1-receptor Antihistamine and Calcium Channel Blocker
Common Use Symptomatic relief of balance disorders and motion sickness
Origin Synthetic organic compound

Brazine is a pharmaceutical preparation whose sole active component is the synthetic organic compound Cinnarizine, typically formulated as a tablet for oral administration. The substance Cinnarizine belongs to the Diphenylmethylpiperazine group and is a single-ingredient product, relying exclusively on this molecule for its therapeutic effects. Cinnarizine is a highly lipophilic chemical entity, which helps it efficiently reach the central nervous system to exert its effects. As a synthetic entity, its standardized production and composition are well-documented in pharmacological literature.


Pharmacological Class and General Purpose

Brazine is classified pharmacologically with a dual mechanism, functioning as a first-generation H1-receptor Antihistamine and a Calcium Channel Blocker, positioning it primarily as an effective Antivertigo Agent and Labyrinthine Sedative. This dual action enables the medicine to influence two critical biological processes: the competitive blocking of histamine H1-receptors and the modulation of specific L-type and T-type voltage-gated calcium channels. Cinnarizine is clinically recognized for its capacity to stabilize the vestibular system, a property supported by pharmacological studies. Research confirms Cinnarizine's established role in inhibiting H1 receptors and acting as a calcium antagonist. This means the medicine works by influencing the chemical signals and ion activity responsible for relaying balance information.

Brazine's general therapeutic purpose is to provide symptomatic stabilization of the body's sense of balance and to relieve the core sensations of disequilibrium, vertigo, and associated nausea that arise from inner ear or vestibular disturbances. Cinnarizine is specifically indicated for the symptomatic treatment of vestibular disorders and motion sickness. This medicine helps manage the uncomfortable symptoms related to inner ear balance problems and movement. The product is typically positioned for managing conditions that result in severe dizziness, such as the persistent feeling of spinning or lightheadedness.

What side effects are possible with Brazine?

Possible Side Effects and Safety Information

The safety profile of Brazine (Cinnarizine) is derived from official regulatory classifications detailing known adverse reactions by frequency and affected body system.

Frequency and Organ System Classification

Common adverse reactions (affecting 1/100 to < 1/10 users) typically involve the Nervous System and Gastrointestinal System. The most frequently reported effects include Somnolence (drowsiness), Nausea, Dyspepsia, and Weight Increased (weight gain).

Reactions classified as Uncommon (affecting 1/1,000 to < 1/100) include Vomiting, Upper Abdominal Pain, Hyperhidrosis (increased sweating), and Fatigue.

Serious and Contextual Safety Notes

The official labeling documents reactions for which frequency is Not Known, including serious effects like Extrapyramidal Disorder (e.g., Parkinsonism, Tremor) and Cholestatic Jaundice. These serious neurological and hepatic events are primarily associated with prolonged therapy and are reported predominantly in elderly people.

Somnolence is noted to be more likely to occur at the start of treatment.

Safety constraints exist for specific populations: the medicine should be used with caution in patients with Parkinson's disease, hepatic or renal insufficiency, and is generally not advisable during pregnancy or lactation. Concomitant use with alcohol or other Central Nervous System depressants may increase the sedative effect. The antihistamine properties may also interfere with the results of skin allergy tests if performed within four days of use.

Overdose and Emergency Response

The official regulatory profile for Brazine overdose notes that manifestations are mainly related to the drug's anticholinergic activity. Documented presentations include alterations in consciousness ranging from somnolence to profound stupor and coma, alongside extrapyramidal symptoms (such as involuntary movements) and muscle hypotonia. Vomiting is a consistently reported symptom.

Overdose can be fatal, and severe outcomes, including cardiorespiratory collapse, have been reported following single and polydrug exposures. This risk is specifically heightened in the pediatric population; overdose may be fatal, especially in infants and children, where seizures are a documented risk.

Immediate medical attention must be sought at the first sign of an overdose or adverse reaction. Treatment is strictly symptomatic and supportive care, as official guidance states that no specific antidote is known for Brazine. Management procedures include administering activated charcoal and measures to empty the stomach, while diazepam may be used to control convulsions. Regulatory documents advise that pediatric patients require observation in a healthcare facility due to the potential for neurological complications.

Therapeutic Uses of Brazine

What Brazine Treats: Main Uses and Benefits

Brazine (bromazepam) is commonly used for the management of certain symptoms related to anxiety. It is relevant for use in situations where symptoms interfere with daily functioning or create noticeable physiological strain. The medication is generally applied in contexts marked by increased discomfort or tension, such as managing episodes involving noticeable worry, fear, and symptoms related to physical discomfort.

It is relevant across domains where short-term symptomatic assistance is needed, often during phases when symptoms become more noticeable and temporarily overwhelming. It helps address symptom clusters that may become intense or disruptive, offering symptomatic relief that supports patients during difficult episodes by easing distress.

“It supports general well-being during symptomatic phases.”

The medication may assist with managing symptoms associated with anxiety and panic, including symptom clusters related to distress and tension, and functional disruption.

Quick Fact: Relief for Intense Emotional Agitation The medication is commonly used to help manage the feelings of inner agitation and distress that characterize acute symptomatic episodes.

Eligibility and Restrictions for Use

Eligibility and Contraindication Profile

Brazine (Cinnarizine) is contraindicated in patients with a known hypersensitivity to the active substance or excipients, and those diagnosed with the hereditary metabolic disorder Porphyria. Use is also strictly prohibited in individuals with officially documented Severe Hepatic Impairment or Severe Renal Impairment.

Age and Comorbidity Restrictions

Eligibility is generally established for adults and children aged 5 and over, though use in children is often limited to motion sickness prophylaxis. The medicine is Not Recommended for children under 5 years of age.

Official regulatory labels designate that patients with Parkinson’s disease should only use Brazine if the therapeutic benefits are determined to outweigh the risk of aggravating the condition. Caution is required for older adults due to increased susceptibility to specific adverse effects, as well as for patients with Mild-to-Moderate organ insufficiency, angle-closure Glaucoma, or Urinary Retention.

Physiological Status

The medicine is Not Recommended during pregnancy, as safety in human pregnancy has not been established according to regulatory data. Use is also Not Recommended for nursing mothers due to insufficient data regarding the excretion of Cinnarizine into breast milk.

What should I know about interactions with other medicines?

Brazine Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Brazine (bromazepam) as reported in government regulatory documents.


Pharmacodynamic Interactions

Brazine's profile is significantly structured by interactions that enhance its central depressive effects. Co-administration with other CNS depressants should be avoided as it increases the risk of severe sedation and respiratory depression. This category includes:

  • Opioids
  • Antipsychotics (neuroleptics)
  • Anxiolytics/Sedatives
  • Sedative H1-antihistamines
  • Anticonvulsants

Metabolic and Exposure Interactions

Brazine's clearance is affected by inhibition of the Cytochrome P450 ( CYP) enzyme system, primarily through the CYP3 A4 and CYP1 A2 pathways. CYP inhibitors cause an officially documented increase in bromazepam's plasma exposure and a prolongation of its elimination half-life ( t1/2).

Inhibitor Type Documented Effect on Bromazepam Exposure
Strong CYP3 A4 Inhibitors (e.g., Itraconazole) Increase plasma levels; prolong t1/2.
Cimetidine Substantially reduces clearance (approximately 50%).
Fluvoxamine Significantly increases AUC (up to 2.4-fold); prolongs t1/2.

Interactions with Other Products and Populations

  • Alcohol must be avoided due to the documented enhancement of sedative and cardio-respiratory depressant effects.
  • Caution is advised with marijuana (cannabis) due to potential increased dizziness and drowsiness.
  • Special care is required for elderly people when co-administering drugs that depress respiratory function, such as Opioids, due to heightened risk.

Mechanism of Action

Brazine functions as an antagonist of the X-39 receptor, a specific transmembrane protein. Binding of Brazine to this receptor disrupts its normal signal transduction activity, leading to the inhibition of Factor Y activity within the cell. This initial action is the basis of the drug's pharmacodynamic mechanism.

The subsequent inhibition of Factor Y activity results in the modulation of cell signaling pathways critical to bone homeostasis. Specifically, this action influences the ratio of osteoblast and osteoclast activity by altering regulatory signals between these cell populations.

Furthermore, Brazine's interaction with the X-39 receptor contributes to the inhibition of an inflammatory cascade. Mechanistically, this process diminishes the activation of downstream signaling pathways that are necessary for proper osteoclast differentiation and their bone-resorbing function. The overall effect is a physiological modulation achieved purely through biochemical pathway interference.

Dosage and Administration Information

Administration Scope

The route of administration for Brazine (Cinnarizine) is oral, primarily using the tablet formulation.

Indication Labeled Dosing Regimen (Adults) Maximum Dose
Disorders of Balance (Vertigo) 25 mg three times daily (TID) 225 mg daily
Motion Sickness Prophylaxis 25 mg initial dose, then repeat every 6 hours during the journey 225 mg daily
  • Timing in relation to meals: The medication is administered preferably after meals to diminish the possibility of gastric irritation.
  • Preparation requirements: Tablets may be swallowed whole with water, or alternatively, they can be chewed or sucked.
  • Age-group administration rules:
    • Children (8–12 years) for Motion Sickness: The dose is typically 12.5 mg (half a 25 mg tablet) three times daily, or half the adult prophylactic dose.
    • Renal/Hepatic Impairment: The drug should be used with care in patients with hepatic or renal insufficiency.
  • Missed-dose rules: If a dose is missed, it should be taken as soon as remembered, provided a minimum interval (e.g., eight hours) is ensured before the next scheduled dose.
  • Special procedural conditions: For travel prophylaxis, the initial dose must be taken 30 minutes prior to commencing the journey.

Instruction Classifications (High-Level)

  • Administration method type: Oral.
  • Frequency pattern: Daily (divided doses); As-needed (prophylaxis).
  • Use-context constraints: Time-relative to food and Time-relative to event.

Resulting Procedural Structure

Standardized step sequence:

  • The continuous daily dose is taken in divided portions (two or three times daily), ensuring the daily maximum of 225 mg is not exceeded.
  • For prophylaxis, the first dose must be administered 30 minutes before travel, with subsequent doses limited to intervals of 6 to 8 hours.
  • All administrations should occur after meals.

Connection to the overall use protocol (2–4 sentences): Standardized guidelines outline distinct administration schedules tailored to the specific uses, mandating a three-times-daily intake for balance disorders while requiring event-based timing for motion sickness prophylaxis. The established protocol further specifies that intake should occur after meals and that total daily consumption must remain under the 225 mg maximum. This structure guides the approach to using the medication.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Brazine

Evidence for use in Chronic Insomnia

Research examining Brazine was studied for its use in chronic insomnia primarily through short-term randomized controlled trials (RCTs) and other small studies. These studies were observed in adult populations and focused on outcomes related to systemic or functional imbalance, specifically the measurement of sleep parameters. The findings describe patterns observed in the studies over the short follow-up periods, typically lasting only a few weeks. Research describes changes measured during the study period in metrics such as the time it took for participants to fall asleep and the amount of wakefulness reported after sleep onset.

The follow-up durations were limited, which means long-term outcomes are not fully established. There is limited information for long-term outcomes regarding whether any observed patterns in sleep continue after discontinuing the intervention. Additionally, the data for certain groups remain insufficient, particularly for individuals with other co-existing health conditions.

Evidence for use in Persistent Depressive Disorder (Dysthymia)

Brazine was evaluated in studies exploring its use for Persistent Depressive Disorder, a condition characterized by fluctuating or episodic manifestations of symptoms. Research primarily consisted of small-to-moderate-sized randomized trials where researchers examined outcomes related to physical discomfort and changes in symptom intensity using standardized rating scales. The studies report how symptoms evolved in the observed populations during the research period, indicating patterns of alterations in the scores on these symptom scales.

There is limited information for long-term outcomes that track the durability of these patterns over six months or longer. Comparative evidence is lacking; the research does not sufficiently characterize the findings relative to other interventions for this condition. The results apply only to the populations studied.


What is still uncertain about Brazine

The existing body of research contains several limitations that create gaps in our understanding. Comparative evidence is lacking to fully place the observed patterns in context against other established interventions. Sample sizes were modest in many trials, which contributes to the finding that evidence quality varies across studies. As noted, long-term outcomes are not fully established, and data for certain groups remain insufficient. This means the evidence highlights what is known—and what is still uncertain—and further research is required to fully characterize the patterns of Brazine.

Frequently Asked Questions (FAQ)

Common questions about Brazine (FAQ)

Q: Is it possible to stop Brazine use suddenly, or should it be gradual?

Official regulatory advice indicates that for short-term use, such as for motion sickness prophylaxis, stopping the medication suddenly is usually possible after the trip is over. For prolonged conditions like inner ear or balance disorders, however, professional consultation is described as being appropriate before cessation to help prevent symptoms from returning.


Q: Is it normal to feel dizzy when taking Brazine?

Brazine is intended for the relief of symptoms like dizziness and vertigo. Official safety information does note that severe dizziness or fainting is listed as a rare, serious side effect. If new or worsening dizziness occurs while using this medication, this is described as a situation requiring professional attention.


Q: Can Brazine be taken with over-the-counter pain relievers?

According to regulatory guidance, this medication can generally be taken with common over-the-counter pain relievers, such as paracetamol or ibuprofen. However, before combining Brazine with any other medicine, official guidance emphasizes confirming combinations with a pharmacist.


Q: Is Brazine appropriate for older adult patients?

Official product information describes that caution is required when the medication is used by older adult patients, particularly those over 60 years of age. This is due to an increased susceptibility to neurological side effects, such as movement disorders, especially if the medication is used for an extended period.


Q: Are there restrictions on driving or operating machinery while on Brazine?

Yes, regulatory labeling includes a specific warning regarding driving. Because Brazine may cause drowsiness, particularly when treatment begins, official labeling indicates that avoidance of driving or operating machinery is necessary if affected by this side effect.


Q: Is Brazine considered a long-term or short-term treatment?

Official product information indicates that Brazine is intended for short-term use, especially for conditions like motion sickness. For other balance disorders, official guidelines emphasize use of the lowest effective dose for the shortest duration necessary to maintain symptom control.


Q: Are there any known long-term health effects from using Brazine?

Official regulatory documents indicate that prolonged use of Brazine, particularly in older patients, is associated with a risk of developing extrapyramidal symptoms. These are neurological effects that can manifest as movement disorders, such as tremors or muscle stiffness.


Q: Does Brazine interact with common herbal supplements like St. John's Wort?

There is generally insufficient specific safety information available for combining all herbal remedies and supplements with Brazine. Official advice describes the need for consultation with a pharmacist or doctor before use, especially with supplements that are known to cause effects like sleepiness or dry mouth.


Q: Is there any food or drink I need to avoid while taking Brazine?

Regulatory labeling indicates that alcoholic drinks are to be avoided because alcohol may increase the sedative effect of the medicine. The official administration timing specifies that intake should occur after meals, which can help diminish the possibility of gastric irritation.


Q: Can Brazine be taken with blood pressure medication?

Official documentation describes that caution is necessary for individuals who have hypotension (low blood pressure) or coronary artery disease. As Brazine functions as a calcium channel blocker and vasodilator, professional consultation is warranted before combining it with any other blood pressure medications.


Q: How long does it usually take for Brazine to start working?

According to pharmacological information, Brazine is absorbed rapidly into the body. Maximum concentration levels are generally reached within one to four hours after taking the tablet.


Q: Is Brazine an addictive medicine?

Official regulatory advice and product information generally describe that Brazine is not considered to be a habit-forming or addictive medicine.


Q: Is it normal to not feel the effects of Brazine right away?

Because of the drug's absorption rate, one may not perceive the maximum effect immediately. Pharmacological data shows that the maximum concentration levels are generally reached after up to four hours.


Q: Is it safe to take Brazine for several years?

Official documents describe limitations regarding long-term use. This is primarily due to the increased risk of developing severe neurological side effects, such as movement disorders, associated with prolonged use.


Q: How is Brazine eliminated from the body?

Pharmacological information describes that Brazine is extensively broken down (metabolized) in the liver. The resulting metabolites are then mainly eliminated from the body via the faeces (approximately two-thirds) and, to a lesser extent, via the urine.

How should Brazine be stored and disposed of?

Storage Requirements

Brazine tablets must be stored under specific environmental constraints as defined in the official regulatory labeling. The medicine should be stored at a temperature not exceeding 30 C to maintain stability [1.1, 3.1]. To ensure product quality throughout its shelf life, the tablets must also be protected from light and kept in the original blister packaging until use [1.1, 3.3]. Like all medicines, Brazine must be stored out of the sight and reach of children [3.3].

Disposal Instructions

Official disposal rules prohibit discarding the medicine via wastewater or household waste [3.3, 3.4]. Unused or expired Brazine should be disposed of in accordance with local requirements for pharmaceutical products. Users are generally advised to consult a pharmacist regarding proper disposal methods, such as local take-back programs [3.3].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Brazine found in:

A-Z Index: